Abstract: The present disclosure relates to a phase shifter and a communication device including the same, and particularly, to a phase shifter including a base panel; a fixed substrate which is laminated and fixed on one side or another side on the base panel and has a plurality of circuit patterns printed on the top surface thereof; and a phase shift switching part provided with a plurality of movable substrates including movable strip terminal which are in contact with the plurality of circuit patterns of the fixed substrate, wherein the phase shift switching part is configured to reciprocate the plurality of movable substrates within a predetermined distance in a horizontal direction on the base panel to change the positions of contact points of the movable substrates with respect to the circuit patterns, wherein the phase shift switching part moves the plurality of movable substrates while elastically supporting the plurality of movable substrates toward the circuit patterns, thereby providing an advantage of maxi

Abstract: A dual polarization antenna is disclosed in at least one embodiment of the present disclosure, including a base substrate, a power feeding unit supported on the base substrate, and a radiating plate supported on the power feeding unit, the power feeding unit includes a first feeding substrate and a second feeding substrate arranged to cross each other on the base substrate, the first feeding substrate includes a first feed line configured to supply a first reference phase signal to a first point on the radiating plate and to supply a first reverse phase signal having a reverse phase relative to the first reference phase signal, to a second point on the radiating plate, the second feeding substrate includes a second feed line configured to supply a second reference phase signal to a third point on the radiating plate and to supply a second reverse phase signal having a reverse phase relative to the second reference phase signal, to a fourth point on the radiating plate, and wherein the first feeding substrate

Abstract: A refrigerator may include a storage compartment, an inner door which comprises an opening having a size corresponding to a size of the storage compartment, a plurality of door guards, and an outer door which open and close the storage compartment, wherein the inner door comprises a control unit may control an internal environment of the storage compartment.

Abstract: The present application relates to an orally administered pharmaceutical composition or kit for eradicating Helicobacter pylori, including a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition and kit of the present invention may further include a ?-lactam antibiotic and/or a gastric acid inhibitor.

Abstract: A pharmaceutical composition for treating Clostridioides difficile Infection (CDI), and a method for producing same. The pharmaceutical composition includes a complex of clay minerals, such as bentonite, and antibiotics, such as vancomycin. Accordingly, the pharmaceutical composition has an excellent treatment effect on CDI even with a significantly smaller amount of each of the existing antibiotics and clay minerals than the maximum recommended daily intake thereof, and has the effect of reducing side effects that can be caused by the massive intake of the antibiotics and clay minerals.

Abstract: According to one embodiment of the present invention, provided is a drug-clay mineral complex, in which the complex comprises a phospholipid, and the drug has an amine group.

Abstract: A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.

Abstract: Provided is a tether anchor assembly for a vehicle including a seat frame including a support panel coupled to a back frame, the support panel including an anchor groove provided therein, and a mounting wire exposed to an outside through the anchor groove, and a tether cover configured to allow the mounting wire to be fitted and coupled to an inside thereof and to be exposed to the outside through the anchor groove when inserted into the anchor groove, and to be directly coupled to the support panel to fix a position of insertion thereof into the anchor groove.

Abstract: Disclosed are a controlled-release composition for oral administration comprising a complex of a hydrophilic alpha adrenergic blocker compound or its salt; and a clay mineral, and a method for preparing the same. The composition of the present disclosure has an in vivo release rate controlled further than that of conventional alpha adrenergic blocker compounds, thereby preventing side effects caused by a rapid increase in plasma drug concentration.

Abstract: Provided is a cosmetic composition comprising bentonite as an active ingredient. The cosmetic composition according to the present disclosure reduces the expression of inflammatory mechanism proteins and inflammatory mechanism genes in keratinocytes and hypodermal cells, exhibits an anti-inflammatory function, increases the moisture content of the skin, reduces redness in the skin, and increases the brightness of the skin, thereby being effective in skin whitening and skin moisturizing.

Abstract: Disclosed is an orally-administered pharmaceutical composition or kit for eradicating Helicobacter pylori comprising a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition or kit of the present disclosure may further comprise a ?-lactam antibiotic and/or a gastric acid-suppressive agent.

Abstract: Provided is a pharmaceutical composition for preventing or treating metabolic bone diseases, containing bentonite as an active ingredient. The present disclosure relates to a composition for inhibiting bone resorption of osteoclasts and simultaneously, promoting bone formation of osteoblasts to be usable in the prevention or treatment of metabolic bone diseases such as osteoporosis, osteomalacia, osteopenia and bone atrophy.

Abstract: The present invention relates to a pharmaceutical composition for prevention, alleviation, and treatment of inflammatory bowel disease, the composition comprising a complex of a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof and a clay mineral; a method for prevention, alleviation, and treatment of inflammatory bowel disease by using same; and a preparation method of the pharmaceutical composition.

Abstract: The present invention relates to a composition for oral administration with controlled release properties, comprising a complex of a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof; and a clay mineral, and a method for preparing same.

Abstract: A composition for dyeing a bentonite, which includes a plant-derived polyphenol, and a method for dyeing a bentonite using the composition are provided. A composition for dyeing a bentonite, which includes a polyphenol such as lignin, pectin, tannin, and catechin, as a plant-derived material, and a method for dyeing a bentonite using the composition are provided.

Abstract: The present application relates to an orally administered pharmaceutical composition or kit for eradicating Helicobacter pylori, including a complex of a non-absorbable antibiotic and a clay mineral. The pharmaceutical composition and kit of the present invention may further include a ?-lactam antibiotic and/or a gastric acid inhibitor.

Abstract: A method for synthesizing high purity montmorillonite is disclosed. According to this synthesis method, bentonite is dissolved in aqua regia to produce a solution and then sodium hydroxide (NaOH) is added to the solution to produce a mixed solution. Then, the mixed solution is kept in a sealed state at a temperature of 90° C. inclusive to 100° C. exclusive to synthesize montmorillonite crystals.

Abstract: A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders; and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.

Abstract: A method for synthesizing high purity montmorillonite is disclosed. According to this synthesis method, bentonite is dissolved in aqua regia to produce a solution and then sodium hydroxide (NaOH) is added to the solution to produce a mixed solution. Then, the mixed solution is kept in a sealed state at a temperature of 90° C. inclusive to 100° C. exclusive to synthesize montmorillonite crystals.